WebBOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development … WebTorbjørn Bjerke. Dr. Torbjørn Bjerke, MD, is a Chairman at SynAct Pharma AB and a Portfolio Manager at Arctic Asset Management AS. He is on the Board of Directors at Biothea Pharma, Inc. At Arctic he has the responsibility of scientific, clinical and regulatory due dilligence of new opportunities and portfolio management and has more than 30 ...
Rohit Mehta - Co-founder and Chief Operating Officer
WebApr 14, 2024 · Brand Insider Summit Pharma & Health July 19 - 22, 2024, Park City OMMA Awards September 28, 2024, NYC TV + Video Insider Summit October 22 - 25, 2024, … WebBryn Pharma USA Private Bryn Pharma, founded in 2016, is a privatelyheld pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine auto-injectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. la ventana san telmo
Biothea Pharma Company Profile: Valuation & Investors
WebApr 3, 2024 · Op 3 april 2024 kondigde SynAct Pharma AB de benoeming aan van de huidige voorzitter van het bedrijf, Torbjørn Bjerke MD, tot nieuwe Chief Executive Officer , met ingang van de jaarlijkse... 10 april 2024 WebFounder of Biothea Pharma, Inc. and Iroko Pharmaceuticals LLC, John F. Vavricka is Chief Commercial Officer for Atea Pharmaceuticals, Inc. In the past he held the position of Chief Executive Officer of Biothea Pharma, Inc., President & Chief Executive Officer of Iroko Pharmaceuticals, Inc., President & Chief Executive Officer for Iroko … WebSep 18, 2024 · At 12 months, the estimated progression-free survival (PFS) rate for trastuzumab deruxtecan (T-DXd) was 75.8% compared with 34.1% in the trastuzumab emtansine (T-DM1) arm, with a hazard ratio of 0 ... la venturosa sa